

## Correlation between the Respiratory Muscle Strength and Six-Minute Walking Distance and Oxidative Stress/Inflammatory Cytokines in Patients with Stable Chronic Obstructive Pulmonary Disease: A Preliminary Study

Jirakrit Leelarungrayub<sup>1</sup>, Rungthip Puntumetakul<sup>2</sup>, Thanyaluck Sriboonreung<sup>1</sup>, Yothin Pothasak<sup>1</sup>, and Jakkrit Klaphajone<sup>3</sup>

<sup>1</sup>Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand; <sup>2</sup>Research Center in Back, Neck, Other Joint Pain and Human Performance (BNOJPH), Khon Kaen University, Khon Kaen 40002, Thailand; <sup>3</sup>Department of Rehabilitation Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

Correspondence: donrawee.leela@cmu.ac.th (J.L.)

*Leelarungrayub J et al. Reactive Oxygen Species 7(20):86–92, 2019; ©2019 Cell Med Press*  
<http://dx.doi.org/10.20455/ros.2019.813>

(Received: September 7, 2018; Revised: October 19, 2018; Accepted: October 22, 2018)

**ABSTRACT** | Chronic obstructive pulmonary disease (COPD) relates to high oxidative stress and inflammation, which may impair physical activity of the patients. However, studies on the relationship of oxidative stress/inflammatory conditions with walking capacity or respiratory muscle strength in COPD patients are lacking. Therefore, the aim of the present study was to evaluate the correlation of respiratory muscle strength (P<sub>Imax</sub>) and walking distance [6-minute walking distance (6MWD)] with oxidative stress parameters [total antioxidant capacity (TAC)], malondialdehyde (MDA), and nitric oxide (NO)] or inflammatory markers [tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-6 (IL-6)]. Twenty-nine stable COPD patients, diagnosed with mild severity, were evaluated twice, one month apart, and the results showed that P<sub>Imax</sub> and the 6MWD had a significantly positive correlation with TAC ( $r = 0.271$ ,  $p = 0.04$ ;  $r = 0.289$ ,  $p = 0.028$ ; respectively). On the other hand, both P<sub>Imax</sub> and the 6MWD had a significantly negative correlation with TNF- $\alpha$  ( $r = -0.558$ ,  $p < 0.001$ ;  $r = -0.587$ ,  $p < 0.001$ ; respectively) and IL-6 ( $r = -0.588$ ,  $p < 0.001$ ;  $r = -0.74$ ,  $p < 0.001$ ; respectively). In addition, the 6MWD showed a significantly negative correlation with MDA ( $r = -0.37$ ,  $p = 0.004$ ). Taken together, this study demonstrated a significant correlation of oxidative stress and inflammation with respiratory muscle strength and walking capacity in COPD patients.

**KEYWORDS** | Chronic obstructive pulmonary disease; Cytokines; Oxidative stress

**ABBREVIATIONS** | 6MWD, six-minute walking distance; CBC, complete blood count; COPD, chronic obstructive pulmonary disease; GSH, reduced form of glutathione; IL-6, interleukin-6; MDA, malondialdehyde; NO, nitric oxide; P<sub>Imax</sub>, maximal inspiratory mouth pressure; TAC, total antioxidant capacity; TNF- $\alpha$ , tumor necrosis factor- $\alpha$

## CONTENTS

1. Introduction
2. Participants and Methods
  - 2.1. Participants
  - 2.2. Oxidative Stress and Cytokine Evaluation
  - 2.3. Respiratory Muscle Strength Test
  - 2.4. Six-Minute Walking Distance Test
  - 2.5. Statistical Analysis
3. Results
4. Discussion

## 1. INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is currently the third most common disease causing death worldwide [1]. Low physical activity from dyspnea, skeletal muscle wasting, decreased respiratory muscle and limb strength [2, 3], decreased exercise capacity [4], and low health-related quality of life are among the chief sequelae of this disease [5]. Oxidative stress and inflammation have been suggested to be major factors involved in the pathogenesis of COPD [6]. In this context, increased lipid peroxide product malondialdehyde (MDA) [7], and decreased glutathione (GSH) and total antioxidant capacity (TAC) were observed in COPD patients [8, 9]. Many cytokines such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-6 (IL-6) can be released in the chronic inflammatory stage of COPD, and may play a role in the disease process [10]. However, the relationship of oxidative stress and inflammatory conditions with walking capacity or respiratory muscle strength in COPD patients had not been previously investigated. Accordingly, the aim of this study was to evaluate the correlation of respiratory muscle strength [as indicated by maximal inspiratory mouth pressure (P<sub>Imax</sub>)] and 6-minute walking distance (6MWD) with oxidative stress and inflammatory cytokines in patients with moderately severe COPD.

## 2. PARTICIPANTS AND METHODS

### 2.1. Participants

This study was carried out with 29 stable COPD patients who were ex-smokers and living at home in

Sansai district, Chiang Mai, Thailand, where data collection or evaluation was performed at the Ban Tor-Public Health Center. The protocol in this study was approved by the Ethic Committee at the Faculty of Associated Medical Sciences, Chiang Mai University, Thailand, and conducted in accordance with the Declaration of Helsinki (2001). The pulmonary function test was repeated twice and evaluated using spirometry (HI-105, Japan) [11]. All of the participants were permitted to receive medication of either a long-acting inhaled bronchodilator or long-acting inhaled steroids, according to the recommendations by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The participants did not present evidence of any hospitalization for uncontrolled hypertension, unstable cardiac disease, recurrent symptoms of acute exacerbation, recurrent pneumothorax, thoracic or chest pain, any liver or renal dysfunction, or endocrinal abnormalities. They were not permitted to take supplements or any extra-nutrients such as multi-vitamins or antioxidant-rich diets within 6 months prior to data collection. All of the participants were asked to self-record their daily food, fluid, and supplement intake in a logbook, and be checked by weekly telephone calls. A stable condition of all the participants had to be confirmed before starting the protocol by screening complete blood count (CBC) at the AMS Clinical Service Center, Faculty of Associated Medical Sciences, Chiang Mai University, Thailand. Blood from the anterior cubital vein was taken and kept in sterile ethylenediamine tetracetic acid (EDTA) for evaluating oxidative stress markers (TAC, MDA, and nitric oxide), and inflammatory cytokines (TNF- $\alpha$  and IL-6). In addition, P<sub>Imax</sub> and the 6MWD also were evaluated. Measurements of all the parameters in this study were taken twice, one month apart.

**TABLE 1. Characteristics, complete blood count, and pulmonary function test in 29 stable COPD participants**

Parameter	Mean $\pm$ SD	Range (min–max)
<i>Characteristics</i>		
Age (years)	72.24 $\pm$ 9.34	46–91
Gender (males/females)	22/7	
BMI (kg.m <sup>-2</sup> )	22.68 $\pm$ 3.78	16.22–30.73
Systolic blood pressure (mm Hg)	121.54 $\pm$ 6.5	100–132
Diastolic blood pressure (mm Hg)	72.76 $\pm$ 10.10	63–97
<i>Complete blood count [reference range]</i>		
WBC (10 <sup>3</sup> /μl) [4.5–11.5]	6.7 $\pm$ 1.3	5.5–9.2
RBC (10 <sup>6</sup> /μl) [3.8–5.3]	4.2 $\pm$ 0.4	3.9–4.9
Hb (g/dl) [10–16]	13.2 $\pm$ 1.4	10.2–15.7
Hct (%) [35–54]	41.5 $\pm$ 1.2	35.2–45.8
PLT (10 <sup>3</sup> /μl) [140–440]	269.0 $\pm$ 29.0	149–395
<i>Pulmonary function test</i>		
FVC (L)	2.11 $\pm$ 0.65	0.77–3.52
FVC (%predicted)	92.43 $\pm$ 14.5	71.43–125.25
FEV1 (L)	1.32 $\pm$ 0.55	0.31–2.37
FEV1 (%predicted)	62.75 $\pm$ 10.45	50–79.23
FEV1/FVC (%predicted)	66.52 $\pm$ 4.53	56.49–78.45
Note: BMI, body mass index; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; Hb, hemoglobin; Hct, hematocrit; PLT, platelet; RBC, red blood cells; WBC, white blood cells.		

## 2.2. Oxidative Stress and Cytokine Evaluation

The plasma from whole fresh blood was separated by centrifugation at 3,000 g for 10 min. Fresh plasma was used to evaluate the TAC, nitric oxide (NO), and MDA by the 2,2'-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) decolorization [12], Griess reagent [13], and thiobarbituric acid (TBA)-reactive substances [14] assays, respectively. Residual plasma was pooled and frozen for determining TNF- $\alpha$  and IL-6 by using human ELISA-kits (Quantikine®, R&D systems, Minneapolis, MN, USA).

## 2.3. Respiratory Muscle Strength Test

Respiratory muscle strength was evaluated by measuring P<sub>Imax</sub> at residual volume, using a portable hand-held mouth pressure meter (MicroRPM, Micro Medical, Kent, UK). The highest data output in units of centimeters in water (cm H<sub>2</sub>O) from three repeated efforts, or a drop of more than 20% from the previous effort, was the criterion for stopping the test [15, 16].

## 2.4. Six-Minute Walking Distance Test

The 6MWD test was evaluated by following the guideline of the American Thoracic Society [17]. A modified protocol of the 20-meter straight walking test was performed in an indoor corridor. Participants were instructed to walk at a comfortable pace for 6 min under supervision of an experienced physiotherapist. They were allowed to stop and rest during the test if feeling strong or heavy dyspnea (equal to 6 from a maximal 10 on the Borge scale), in accordance with the guideline of the American College of Sport Medicine (ACSM, 2004) [18].

## 2.5. Statistical Analysis

All data were analyzed statistically for normal distribution, using the one-sample Kolomogorov–Smirnov test, before presenting as mean with standard deviation (SD), and minimal and maximal values. Correlation of P<sub>Imax</sub> and the 6MWD tests with oxidative stress parameters and cytokines was analyzed by Pearson's correlation test. All the statistical analyses

**TABLE 2. Parameters of PImax, 6MWD, TNF- $\alpha$ , IL-6, TAC, MDA, and NO measured twice in 29 stable COPD patients**

Parameter	Mean $\pm$ SD	Range (min–max)
PImax (cm H <sub>2</sub> O)	71.58 $\pm$ 23.09	25–135
6MWD (m)	324.98 $\pm$ 94.58	110–523
TNF- $\alpha$ (ng/ml)	10.08 $\pm$ 3.69	4.5–17.6
IL-6 (ng/ml)	7.76 $\pm$ 3.66	2.6–15.60
TAC (mM Trolox)	1.13 $\pm$ 0.06	1.0–1.31
MDA ( $\mu$ M)	6.52 $\pm$ 2.66	2.4–14.96
NO ( $\mu$ M)	5.0 $\pm$ 3.25	1.5– 0.35

were carried out using the statistical package for social science software (SPSS) version 17.0 (SPSS Inc., Chicago, IL, USA). A p value of  $< 0.05$  is considered statistically significant.

### 3. RESULTS

The results of patients' characteristics, CBC, and pulmonary function test are shown in **Table 1**. The blood pressure results were within the reference range indicating a stable cardiovascular condition before collection of all the parameters in this study. Moreover, results of the CBC were within the reference value before starting the protocol. Pulmonary function test indicated a moderate severity.


The results of PImax, 6MWD, TNF- $\alpha$ , IL-6, TAC, MDA, and NO are presented in **Table 2**. The correlation analysis showed that PImax and 6MWD had a significantly low direct linear relationship with TAC ( $r = 0.271$ ,  $p = 0.04$ ;  $r = 0.289$ ,  $p = 0.028$ ; respectively) (**Figure 1**). On the other hand, PImax and 6MWD showed a significantly moderate inverse linear relationship with TNF- $\alpha$  ( $r = -0.558$ ,  $p < 0.001$ ;  $r = -0.587$ ,  $p < 0.001$ ; respectively) and IL-6 ( $r = -0.588$ ,  $p < 0.001$ ;  $r = -0.74$ ,  $p < 0.001$ ; respectively) (**Figure 2**). Furthermore, a significantly low inverse linear relationship between 6MWD and MDA was observed (**Figure 3**). However, PImax did not correlate with NO ( $r = 0.207$ ,  $p = 0.12$ ), and neither did the 6MWD ( $r = -0.185$ ,  $p = 0.164$ ) (figure not shown).

### 4. DISCUSSION


This preliminary study showed the correlation between parameters of physical assessment and bio-

chemical markers that relate to oxidative stress and inflammatory conditions in COPD patients with moderate severity. Due to the small sample size of 29 participants, evaluation was carried out twice, one month apart, for confirmation of the validity of the results. Up to now, no study had investigated the correlation between oxidative stress or inflammatory conditions and physical function among COPD patients. Previous studies only reported that increased lipid peroxide product MDA [7] and decreased GSH or TAC were found in COPD patients [8, 9], as were inflammatory markers such as TNF- $\alpha$  and IL-6 [10]. This study demonstrated a significantly inverse correlation of PImax and 6MWD with cytokines (TNF- $\alpha$  and IL-6). The possible correlation of respiratory muscle and leg muscle strength with inflammation is of interest. The results of this study were in line with those in a previous one that showed a correlation between TNF- $\alpha$  and COPD severity [19] and suggested that a higher level of TNF- $\alpha$  might predict not only worse lung severity, but also possible respiratory muscle strength or walking capacity. Furthermore, the results of the present study also showed a possible correlation between TAC and walking distance, and a negative correlation between MDA and walking distance, which together suggested that low inflammation, low lipid peroxidation, and high antioxidant status might improve walking capacity. The causal relationship between them, however, warrants further investigation.

This study did not show a correlation of PImax and 6MWD with NO. As a vasodilator, NO may affect muscle strength via modulating blood flow. A previous study proposed that NO was associated with pathological pathways and possibly predicted airway obstruction depending on disease severity of COPD [20]. The reason for the lack of a correlation between



**FIGURE 1.** Correlation between PImax (cm H<sub>2</sub>O)/6MWD (m) and TAC (mM Trolox). There were 58 data points from two repeated measurements in 29 COPD patients. Data were statistically analyzed by the Pearson correlation test.




**FIGURE 2.** Correlation between PImax (cm H<sub>2</sub>O)/6MWD (m) and TNF- $\alpha$  (ng/ml)/IL-6 (ng/ml). There were 58 data points from two repeated measurements in 29 COPD patients. Data were statistically analyzed by the Pearson correlation test.

NO and physical capacity in this study was unclear. Other researchers reported that NO did not differ among severe COPD patients because there was no inducible NO synthase in any muscle, when compared to non-COPD patients [21]. Nevertheless, the results of the present study revealed a significant

correlation between oxidative/inflammatory stress parameters and the physical functionality of the COPD patients, which might provide new insight into the pathophysiology of COPD and the development of mechanistically based intervention for this disorder.





**FIGURE 3. Correlation between 6MWD (m) and MDA ( $\mu\text{M}$ ).** There were 58 data points from two repeated measurements in 29 COPD patients. Data were statistically analyzed by the Pearson correlation test.

## ACKNOWLEDGMENTS

This study received a grant from the Research Center in Back, Neck, Other Joint Pain and Human Performance (BNOJPH), Khon Kaen University, Khon Kaen, Thailand. The authors thank all of the subjects and caregivers for their assistance in helping to control and organize the training with good consistency. Thanks also go to all of the physical therapists at Sansai Hospital, Chiang Mai province who organized space for collecting data. The authors declared no conflicts of interest.

## REFERENCES

1. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. *N Engl J Med* 2009; 360(23):2445–54. doi: 10.1056/NEJMra0804752.
2. Gosselink R, De Vos J, van den Heuvel SP, Segers J, Decramer M, Kwakkel G. Impact of inspiratory muscle training in patients with COPD: what is the evidence? *Eur Respir J* 2011; 37(2):416–25. doi: 10.1183/09031936.00031810.
3. Klimathianaki M, Vaporidi K, Georgopoulos D. Respiratory muscle dysfunction in COPD: from muscles to cell. *Curr Drug Targets* 2011; 12(4):478–88.
4. Lacasse Y, Martin S, Lasserson TJ, Goldstein RS. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease: a Cochrane systematic review. *Eura Medicophys* 2007; 43(4):475–85.
5. Peruzza S, Sergi G, Vianello A, Pisent C, Tiozzo F, Manzan A, et al. Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life. *Respir Med* 2003; 97(6):612–7.
6. Domej W, Oetl K, Renner W. Oxidative stress and free radicals in COPD: implications and relevance for treatment. *Int J Chron Obstruct Pulmon Dis* 2014; 9:1207–24. doi: 10.2147/COPD.S51226.
7. Kirkham PA, Barnes PJ. Oxidative stress in COPD. *Chest* 2013; 144(1):266–73. doi: 10.1378/chest.12-2664.
8. Ahmadi Hosseini SH, Farzac M, Heydari A. Comparing the effect of resistive inspiratory muscle training and incentive spirometry on respiratory pattern in COPD patients. *Evi Based Care J* 2016; 6(3):45–54. doi: 10.22038/EBCJ.2016.7654.
9. Nadeem A, Raj HG, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in chronic obstructive pulmonary disease. *Inflammation* 2005; 29(1):23–32. doi: 10.1007/s10753-006-8965-3.
10. Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease. *Caspian J Intern Med* 2012; 3(2):428–35.
11. American Thoracic Society. Standardization of Spirometry, 1994 Update. *Am J Respir Crit Care Med* 1995; 152(3):1107–36. doi: 10.1164/ajrccm.152.3.7663792.
12. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radic Biol Med* 1999; 26(9–10):1231–7.
13. Leelarungrayub J, Laskin JJ, Bloomer RJ, Pinkaew D. Consumption of star fruit juice on pro-inflammatory markers and walking distance in the community dwelling elderly. *Arch Gerontol Geriatr* 2016; 64:6–12. doi: 10.1016/j.archger.2015.12.001.

14. Chirico S. High-performance liquid chromatography-based thiobarbituric acid tests. *Methods Enzymol* 1994; 233:314–8.
15. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. *Am Rev Respir Dis* 1969; 99(5):696–702. doi: 10.1164/arrd.1969.99.5.696.
16. Evans JA, Whitelaw WA. The assessment of maximal respiratory mouth pressures in adults. *Respir Care* 2009; 54(10):1348–59.
17. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166(1):111–7. doi: 10.1164/ajrccm.166.1.at1102.
18. American College of Sport Medicine. *ACSM's Guidelines for Exercise Testing and Prescription*. Lippincott Williams & Wilkins, Philadelphia, PA, USA. 2004.
19. Singh S, Verma SK, Kumar S, Ahmad MK, Nischal A, Singh SK, et al. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers. *Immunol Lett* 2018; 196:1–10. doi: 10.1016/j.imlet.2018.01.004.
20. ben Anes A, Fetoui H, Bchir S, ben Nasr H, Chahdoura H, Chabchoub E, et al. Increased oxidative stress and altered levels of nitric oxide and peroxynitrite in Tunisian patients with chronic obstructive pulmonary disease: correlation with disease severity and airflow obstruction. *Biol Trace Elem Res* 2014; 161(1):20–31. doi: 10.1007/s12011-014-0087-4.
21. Barreiro E, de la Puente B, Minguella J, Corominas JM, Serrano S, Hussain SN, et al. Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005; 171(10):1116–24. doi: 10.1164/rccm.200407-887OC.